Home Business Innate Pharma, strongest rise in the SRD market at mid-session on Monday...

Innate Pharma, strongest rise in the SRD market at mid-session on Monday January 16, 2023 –

0
Innate Pharma, strongest rise in the SRD market at mid-session on Monday January 16, 2023 -

(AOF) – Innate Pharma (+11.07% to 3.71 euros)

Innate Pharma leads the SRD market mid-session after announcing the publication of encouraging preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NK cell engaging (“Natural Killer”) cell engaging antibody. Innate develops via its proprietary platform Anketim a large portfolio of NK cell engagers that can address different types of cancer. Innate Pharma posted an increase of more than 17% over five days, and more than 34% over six months, but remains down more than 7% over one year.

LEAVE A REPLY

Please enter your comment!
Please enter your name here